Arena Pharmaceuticals Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Arena Pharmaceuticals Inc
Access all reports
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company offers BELVIQ, a serotonin 2C receptor agonist approved for marketing in the United States; Belviq XR, an extended-release formulation of lorcaserin; APD334 that is in phase II clinical study for treating autoimmune diseases, including ulcerative colitis and Crohn's disease; APD371 for the treatment of patients with pain associated with Crohn's disease; and APD811, which is in phase I clinical stage to treat pulmonary arterial hypertension. It also develops ralinepag (APD811), which has completed phase II clinical stage for the treatment of pulmonary arterial hypertension.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ARNA
Country
🇺🇸 United States